State data quality matrix - Sept. '20: 4 months after we last published the data elements published by states in their Covid19 daily bulletins, we take a look at the state of data as of Sept.
Refer attached images for the matrix and ensuing thread for a brief commentary.
➡️ Change in phase of pandemic, leads to changes in reporting: Details like demographics, contact details of patients have been dropped by states that used to publish it as cases increased. Other data points like bed availability, test type breakdown etc. have been added.
2/8
➡️ Need for a minimum national reporting standard: Still, wide variance is seen in data points reported by states. 6 months in, some states do not report critical category like breakdown by districts. Calls for a national reporting standard of minimum required data fields.
3/8
➡️ Standardization of terms, methodologies and timelines: Comparison between states become difficult when these are not standardized. Some states report data from 9am to 9am, some from 5pm to 5pm, while some report previous day's data the next day.
4/8
➡️ Clarity for testing data: With increased use of RATs, the need to report test types and +ves by test type has become important off late. Very few states publish this. Standardisation of reporting standard required here so that all states declare breakdown by test type.
5/8
➡️ Health Infra data: As cases have increased, data on capacity and availability of hospital beds, ICU beds, O2 beds etc. have become important. Multiple states include this data now and will be good for others to adopt.
6/8
Non personally identifiable demographic data: Data points like age, gender, symptoms, duration of hospitalisation, co-morbidities etc. are critical for prescriptive analysis. Very few states publish this, limiting analysis and interventions based on critical demographic data
7/8
6 months - In retrospect: A central directive on data reporting standards, conventions, definitions, timeline etc. would have enabled a uniform and comparable data reporting paradigm across states/UTs. Will we see that in the coming months?
8/8
• • •
Missing some Tweet in this thread? You can try to
force a refresh
What will happen to covid19india.org after October 31st? Some pointers:
* There will be no data updates from 1st Nov, 2021 (sigh!).
* The website will be up and available for referencing past data.
* The website/operations are not being handed over to any group.
1/4
* Our team will wind down and we will be limiting our interactions on email and twitter. We will monitor communications occassionally and will try to respond to critical messages.
* With minimal involvement, we are constrained to respond to requests for interviews/talks.
2/4
* Why don't you convert the website to track broader health data?
This is an audacious goal, but our team is not invested into public health. Our work is open sourced. Groups with interest in public health can utilise our code to build broader public health data platforms.
3/4
Latest data from @PHE_uk on vaccine efficacy (VE) against HOSPITALISATION for the Delta variant.
VE for Covishield against hospitalisation:
✅ After 1 dose: 71%
✅ After 2 doses: 92%
❓Wasn't the reported efficacy lower against Delta? What has changed?
1/4
Vaccine efficacy can be measured against different endpoints. There can be efficacy against hospitalisation, against death, against symptomatic infection etc.
Earlier studies from the UK, had reported VE against SYMPTOMATIC INFECTION.
This is VE against hospitalisation.
2/4
Putting both these studies together:
VE for Covishield towards Delta variant:
✅ After 1 dose:
📌 Against symptomatic infection: 33%
📌 Against hospitalisation: 71%
✅ After 2 doses:
📌Against symptomatic infection: 60%
📌 Against hospitalisation: 92%
3/4
On breakthrough infections, vaccines and gap between doses:
A correspondence published in NEJM on 2nd June, details a study on breakthrough infections with a large cohort of 7000+ healthcare workers in a tertiary hospital in India.
7000+ received the first dose and 3600+ of them subsequently got the 2nd dose.
Vaccine administered was Covishield.
An additional 5000+ were not vaccinated.
Study period: Jan-Apr 2021.
📌 506 HCWs tested +ve during the study, of which 64% were unvaccinated.
2/n
📌 Of the 7000+ HCWs that got the 1st dose, only 2.6% of them tested positive.
📌 3600+ HCWs got both doses and 2% of them tested positive.
📌 Breakthrough infection, measured as those testing positive 14 days after both doses stood at 1.6%.
3/n
If you do not have any symptoms 14 days after confirmation of Covid, a repeat test IS NOT required.
1/n
❓When can I consider myself recovered from Covid?
➡️ 14 days after date of test.
➡️ 3 consecutive days of no symptoms.
➡️ If you had severe symptoms, consult your doctor for discharge criteria.
➡️ No need for a repeat RTPCR test.
2/n
❓Do I need to continue wearing masks inside my home after recovery?
No. One does not generally transmit the virus after Day 10 of infection. After 14 days of room quarantine, there is no need to wear a #mask inside the house.
3/n
A quick overview of Biological E.'s Covid vaccine:
✅ Vaccine platform: Protein Subunit.
✅ Number of doses: 2 doses
✅ Gap between doses: 28 days*
✅ Current status: Completed Phase 1 and 2 trials. Got approval for Phase 3 trials in April 2021.
*As per clinical trials.
1/n
✅ Partnership: Antigen developed by Texas Children's Hospital for Vaccine Development and Baylor College of Medicine. Adjuvant supplied by Dynavax Technologies (US).
✅ Proven platform used for Hepatitis B vaccine. Novavax vaccine also uses subunit technology.
2/n
✅ What is a protein subunit vaccine?
It consists of specific parts of the SARS-Cov-2 antigen that are synthesized and harvested in a medium like yeast. The proteins themselves elicit weak immune response and they need an adjuvant added to augment the immune response.